A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson’s disease

Parkinson’s disease (PD) is slowly progressing neurodegenerative disorder that affects millions of patients worldwide. While effective symptomatic therapies for PD exist, there is no currently available disease modifying agent to slow or stop the progression of the disease. Many years of research fr...

Full description

Saved in:
Bibliographic Details
Published inGlycoconjugate journal Vol. 39; no. 1; pp. 13 - 26
Main Author Schneider, J. S.
Format Journal Article
LanguageEnglish
Published New York Springer US 01.02.2022
Springer Nature B.V
Subjects
Biochemistry
Biomedical and Life Sciences
Comprehensive Review Article
Ganglioside GM1
Gangliosides
Life Sciences
Movement disorders
Neurodegenerative diseases
Parkinson's disease
Pathology
The Glycobiology of Parkinson’s disease
Neuroprotection
GM1
Ganglioside
Parkinson’s disease
Online AccessGet full text

Cover

More Information
Summary:Parkinson’s disease (PD) is slowly progressing neurodegenerative disorder that affects millions of patients worldwide. While effective symptomatic therapies for PD exist, there is no currently available disease modifying agent to slow or stop the progression of the disease. Many years of research from various laboratories around the world have provided evidence in favor of the potential ability of GM1 ganglioside to be a disease modifying agent for PD. In this paper, information supporting the use of GM1 as a disease modifying therapeutic for PD is reviewed along with information concerning the role that deficiencies in GM1 ganglioside (and potentially other important brain gangliosides) may play in the pathogenesis of PD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0282-0080
1573-4986
1573-4986
DOI:10.1007/s10719-021-10002-2